Although M2 macrophages exhibited higher mobility after priming with CM from MCT-1-overexpressing MDA-MB-231 (IV2-3) cells (Fig. 5A), the MitoQ-treated cancer cells inhibited the mobility of M2 macrophages. Here, MCTS1 is linked to cancer.